ALZN

Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro, Inc. (ALZN) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (C-). The rating has held at C+ for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.4
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -22.4%
Price Return 12M -49.4%
Catalyst Signal 0.00
Market Cap $5.7M
TTM Revenue N/A
Price / Sales N/A
ROE -163.2%

Historical Factor Score Progression

Held C+ for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C- (2.1) C (2.2) C+ (2.8) C+ (2.6) C+ (2.7)
2026-11-10 A- (3.9) C- (2.1) C (2.2) B- (3.0) C+ (2.6) C+ (2.8)
2026-11-03 B+ (3.7) C- (2.1) C (2.3) C+ (2.8) C+ (2.7) C+ (2.7)
2026-10-27 B+ (3.7) C- (2.1) C (2.4) B (3.2) C+ (2.6) C+ (2.8)
2026-10-20 B+ (3.7) C- (2.1) C (2.3) B (3.4) C+ (2.6) C+ (2.8)
Page 1 of 4